In addition, ARNTL2 was expressed at low levels in only three cancer types, including adrenocortical carcinoma (ACC), prostate adenocarcinoma (PRAD), and skin cutaneous melanoma (SKCM) (Figure 1A). This evidence concerns the gene BMAL2 and prostate adenocarcinoma.